VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
MLSS
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
MLSSMilestone Scientific Inc.
$0.32$28M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksMLSSFinancials

Milestone Scientific Inc. (MLSS) Financials

30Y historyFree accessUpdated daily

Despite maintaining a robust 71.4% gross margin in 2026Q1, the company remains trapped in a cycle of negative profitability with an operating margin of -38.3% due to excessive overhead costs.

MLSS Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Sales/Revenue8.9M8.97M8.63M9.83M8.81M10.3M5.44M8.37M9.62M11.28M10.48M9.49M10.33M10.01M8.65M8.38M9.75M8.55M6.62M6.39M5.84M6.43M4.75M3.97M4.07M4.09M5.67M2.86M8.8M2.9M300K
Revenue Growth %3.37%3.99%-12.19%11.6%-14.54%89.52%-35.07%-12.97%-14.71%7.63%10.43%-8.14%3.21%15.76%3.22%-14.07%14.05%29.07%3.65%9.35%-9.16%35.4%19.63%-2.51%-0.48%-27.86%98.72%-67.55%203.45%866.67%-
Cost of Goods Sold2.64M2.64M2.2M3.03M3.91M3.99M1.82M2.66M5.19M4.31M4.18M3.05M3.63M3.2M3.06M3.02M3.53M3.46M2.68M2.9M3.04M2.52M2.42M2M1.98M1.97M2.91M839.46K9.6M1.6M0
COGS % of Revenue-29.47%25.44%30.88%44.35%38.75%33.4%31.72%53.95%38.23%39.84%32.12%35.14%31.95%35.34%36.01%36.22%40.45%40.48%45.35%51.94%39.19%50.85%50.44%48.62%48.2%51.25%29.4%109.09%55.17%-
Gross Profit6.27M6.33M6.43M6.79M4.9M6.31M3.62M5.72M4.43M6.97M6.31M6.44M6.7M6.81M5.59M5.36M6.22M5.09M3.94M3.49M2.81M3.91M2.34M1.97M2.09M2.12M2.77M2.02M-800K1.3M300K
Gross Margin %70.37%70.53%74.56%69.12%55.65%61.25%66.6%68.28%46.05%61.77%60.16%67.88%64.86%68.05%64.66%63.99%63.78%59.55%59.52%54.65%48.06%60.81%49.15%49.56%51.38%51.8%48.75%70.6%-9.09%44.83%100%
Gross Profit Growth %--1.64%-5.27%38.6%-22.36%74.3%-36.67%29.04%-36.42%10.51%-2.12%-3.86%-1.62%21.82%4.3%-13.78%22.15%29.12%12.88%24.36%-28.21%67.52%18.63%-5.95%-1.3%-23.34%37.21%352%-161.54%333.33%-
Operating Expenses10.79M12.03M13.19M13.9M13.73M13.69M11.07M9.72M10.89M12.2M12.82M9.5M7.49M5.73M6.11M6.59M6.92M7.19M5.67M6.73M6.33M7.08M5.34M3.7M3.76M5.32M9.6M8.2M10.2M9M2.6M
OpEx % of Revenue-134.01%152.86%141.43%155.9%132.86%203.68%116.03%113.19%108.17%122.31%100.09%72.51%57.19%70.68%78.6%70.97%84.15%85.62%105.35%108.34%110.06%112.47%93.17%92.36%129.98%169.23%287.09%115.91%310.34%866.67%
Selling, General & Admin10.69M11.58M000009.53M10.65M11.93M11.55M9.4M7.4M5.53M5.93M6.45M6.65M6.95M5.5M6.34M5.33M6.79M5.16M3.57M3.59M5.27M8.5M7.01M9.3M7.7M2.2M
SG&A % of Revenue-129%-----113.77%110.63%105.75%110.19%99.03%71.66%55.28%68.58%76.93%68.19%81.33%83.08%99.14%91.13%105.61%108.51%89.88%88.09%128.76%149.76%245.48%105.68%265.52%733.33%
Research & Development80.35K449.47K858.77K701.38K1.15M878.21K307.85K189.92K245.64K272.75K1.27M100.86K88.24K191.34K181.98K140.05K270.49K241.32K168.52K397.35K1.01M286.26K187.99K131.01K147.71K49.94K386.25K455.33K400K1M200K
R&D % of Revenue-5.01%9.95%7.14%13.06%8.52%5.66%2.27%2.55%2.42%12.12%1.06%0.85%1.91%2.1%1.67%2.77%2.82%2.54%6.22%17.2%4.45%3.96%3.3%3.63%1.22%6.81%15.95%4.55%34.48%66.67%
Other Operating Expenses19.5K012.33M13.2M12.58M12.81M10.77M0-7.23K-4.93K-5.09K-5.35K017.54K000000000026.07K0718.62K732.86K500K300K200K
Operating Income-4.53M-5.7M-6.76M-7.11M-8.83M-7.38M-7.45M-4M-8M-5.23M-6.51M-3.06M-790.18K1.09M-520.35K-1.22M-700.84K-2.1M-1.73M-3.24M-3.52M-3.25M-3.01M-1.73M-1.67M-3.2M-6.84M-6.18M-11M-7.7M-2.3M
Operating Margin %-50.84%-63.48%-78.3%-72.31%-100.24%-71.6%-137.08%-47.75%-83.14%-46.4%-62.14%-32.2%-7.65%10.85%-6.02%-14.6%-7.19%-24.61%-26.1%-50.7%-60.28%-50.47%-63.31%-43.61%-40.98%-78.18%-120.48%-216.49%-125%-265.52%-766.67%
Operating Income Growth %-15.69%4.92%19.5%-19.64%1%-86.37%50.01%-52.82%19.64%-113.1%-286.84%-172.71%308.84%57.47%-74.59%66.68%-21.69%46.65%8.02%-8.49%-7.94%-73.68%-3.74%47.83%53.19%-10.59%43.8%-42.86%-234.78%-
EBITDA-4.34M-5.51M-6.72M-7.04M-8.76M-7.3M-7.36M-3.74M-7.12M-4.66M-6.35M-2.96M-694.34K1.18M-425.22K-1.12M-572.2K-1.98M-1.6M-3.09M-3.4M-3.13M-2.91M-1.4M-1.25M-2.77M-6.12M-5.45M-10.5M-7.4M-2.1M
EBITDA Margin %-48.73%-61.41%-77.86%-71.68%-99.52%-70.89%-135.31%-44.69%-73.98%-41.32%-60.59%-31.18%-6.72%11.81%-4.92%-13.35%-5.87%-23.13%-24.18%-48.37%-58.25%-48.64%-61.17%-35.17%-30.72%-67.55%-107.82%-190.82%-119.32%-255.17%-700%
EBITDA Growth %39.69%17.99%4.61%19.62%-19.97%0.71%-96.58%47.42%-52.71%26.6%-114.59%-326.22%-158.7%378.17%61.97%-95.42%71.06%-23.47%48.2%9.19%-8.79%-7.66%-108.06%-11.61%54.74%54.8%-12.28%48.11%-41.89%-252.38%-
D&A (Non-Cash Add-back)188.38K185.66K37.45K62.32K63.84K73.83K95.95K256.47K881.28K573.15K163.37K97.38K95.84K96.12K95.13K105.39K128.64K126.39K127.24K148.91K118.76K118.15K101.92K335.22K417.99K435.18K718.62K732.86K500K300K200K
EBIT-4.53M-5.7M-6.76M-7.11M-8.83M-7.38M-7.45M-7.64M-6.46M-5.23M-6.51M-3.06M-790.18K1.54M-691.34K-1.34M-700.84K-2.1M-1.73M-3.24M-3.52M-3.25M-3.01M-1.73M-1.67M-3.2M-6.84M-6.18M-11M-7.5M-2.3M
Net Interest Income-40.64K-25.6K60.27K125.53K54.61K-16.36K-18.08K1.54K7.45K9.3K1.28K3.84K2.39K-70.69K-178.94K-137.1K-94.55K-150.88K-107.35K000000000000
Interest Income1.52K060.27K125.53K54.61K001.54K7.45K9.3K1.28K3.84K5.06K11534355873.15K9.02K087.41K0000000000
Interest Expense42.16K25.6K00016.36K18.08K000002.67K70.8K178.97K131.84K95.14K154.03K116.37K000000000000
Other Income/Expense-40.64K-25.6K2.04M125.53K54.61K502.41K79.81K-3.56M2154.37K-3.8K-1.51K-907.81K378.23K-349.95K-258.5K86.33K573.43K541.13K301.55K370.52K492.87K11.34K053.93K64.49K-246.28K-807.6K400K0200K
Pretax Income-4.57M-5.72M-4.71M-6.98M-8.77M-6.88M-7.37M-7.56M-8M-5.23M-6.52M-3.06M-1.7M1.46M-870.31K-1.35M-519.96K-2.16M-1.08M-2.94M-3.15M-2.27M00-1.62M-3.14M-7.08M-6.99M-10.6M-7.5M-2.1M
Pretax Margin %-51.3%-63.76%-54.62%-71.04%-99.62%-66.73%-135.61%-90.3%-83.13%-46.36%-62.18%-32.22%-16.43%14.63%-10.06%-16.12%-5.33%-25.23%-16.31%-45.98%-53.94%-35.26%---39.66%-76.6%-124.82%-244.77%-120.45%-258.62%-700%
Income Tax0000033315.5K18.13K23.99K19.09K-19.1K36.16K9.51K07.95K258.5K-86.33K-573.43K-541.13K00-413.94K-11.34K680.86K770.64K791.16K673.22K790.58K-300K-300K-400K
Effective Tax Rate %0%0%0%0%0%-0%-0.21%-0.24%-0.3%-0.37%0.29%-1.18%-0.56%0%-0.91%-19.14%16.6%26.59%50.1%0%0%18.25%---47.7%-25.23%-9.5%-11.31%2.83%4%19.05%
Net Income-4.57M-5.72M-4.71M-6.93M-8.71M-6.82M-7.34M-7.52M-7.43M-5.19M-5.95M-5.47M-1.7M1.46M-870.31K-1.48M-614.51K-1.53M-1.19M-2.94M-3.15M-2.75M-3M-2.41M-2.44M-3.99M-7.51M-6.97M-10.7M-7.4M-1.9M
Net Margin %-51.3%-63.76%-54.62%-70.51%-98.87%-66.17%-134.94%-89.85%-77.24%-45.97%-56.73%-57.6%-16.47%14.63%-10.06%-17.69%-6.3%-17.9%-17.93%-45.98%-53.94%-42.81%-63.08%-60.75%-59.9%-97.51%-132.35%-244.17%-121.59%-255.17%-633.33%
Net Income Growth %13.29%-21.4%31.97%20.41%-27.69%7.07%2.49%-1.25%-43.28%12.78%-8.76%-221.24%-216.18%268.32%41.28%-141.18%59.84%-28.85%59.59%6.78%-14.45%8.1%-24.2%1.12%38.87%46.85%-7.71%34.84%-44.59%-289.47%-
Net Income (Continuing)-4.57M-5.72M-4.71M-6.98M-8.77M-6.88M-7.39M-7.58M-7.69M-5.37M-7.29M-5.54M-1.71M1.46M-870.31K-1.48M-614.51K-1.53M-1.19M-2.94M-3.15M-2.75M-3M-2.41M-2.44M-3.99M-7.51M-6.97M-10.7M-7.4M-1.9M
Discontinued Operations0000000000000000000000000000000
Minority Interest0000-219.28K-152.54K-94.43K-67.27K-11.4K256.74K36.11K-1.14M394.53K000000000000000000
EPS (Diluted)-0.06-0.07-0.06-0.10-0.12-0.10-0.12-0.17-0.21-0.16-0.22-0.26-0.080.08-0.05-0.10-0.04-0.11-0.09-0.24-0.27-0.25-0.33-0.52-0.59-1.07-2.15-2.40-3.66-3.63-1.29
EPS Growth %14.68%-18.44%37.92%20.67%-20%16.67%29.41%19.05%-31.25%27.27%15.38%-206.6%-206%247.87%44.63%-135.42%62.27%-17.4%60.96%11.11%-8%24.24%36.54%11.86%44.86%50.23%10.42%34.43%-0.83%-181.4%-
EPS (Basic)--0.07-0.06-0.10-0.12-0.10-0.12-0.17-0.21-0.16-0.22-0.26-0.080.09-0.05-0.10-0.04-0.11-0.09-0.24-0.27-0.25-0.33-0.52-0.59-1.07-2.15-2.40-3.66-3.63-1.29
Diluted Shares Outstanding82.06M82.06M79.79M72.78M70.61M68.83M63.06M45.74M35.3M32.7M26.97M21.43M20.06M17.48M16.08M15.17M14.82M13.39M12.67M12.14M11.79M11.01M9.15M4.67M4.16M3.71M3.5M2.91M2.92M2.04M1.47M
Basic Shares Outstanding82.06M82.06M79.79M72.78M70.61M68.83M63.06M45.74M35.3M32.7M26.97M21.03M20.06M17.13M16.08M15.17M14.82M13.39M12.67M12.14M11.79M11.01M9.15M4.67M4.16M3.71M3.5M2.91M2.92M2.04M1.47M
Dividend Payout Ratio-------------------------------

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Liquidity and scaling constraints

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Stagnant Revenue Amidst Volatile Demand

According to recent financial disclosures, Milestone Scientific's revenue growth has remained inconsistent, with the most recent quarterly figure of $2.2 million representing a 3.99% year-over-year decline, highlighting the difficulty in scaling the company's proprietary medical device technology within a highly competitive and mature dental market.

The lack of consistent top-line expansion suggests that the company's razor-razorblade model is struggling to gain sufficient traction to offset the cyclical nature of dental equipment procurement. Investors should monitor whether the current revenue plateau reflects a saturation of the existing dental base or a failure to successfully penetrate the broader medical segment.

High Gross Margins Mask Inefficiency

As reported in financial statements, Milestone Scientific maintains a robust gross margin of approximately 70%, yet this premium pricing power is effectively neutralized by an operating margin that has remained deeply negative, recently hovering around -63% due to substantial overhead and specialized sales force requirements.

While the high gross margin confirms the value proposition of the proprietary disposable handpieces, the inability to convert this into operating profitability indicates a structural mismatch between production costs and commercialization expenses. This disparity suggests that the company's current scale is insufficient to absorb the fixed costs inherent in its specialized medical device business model.

Operating Leverage Remains Elusive

Based on the company's reported figures, operating expenses continue to dwarf gross profit, with SG&A costs frequently exceeding $2.5 million per quarter, which prevents the firm from achieving the necessary operating leverage to reach a break-even point despite the high-margin nature of its core product offerings.

The persistent reliance on heavy SG&A spending to drive clinical education and market adoption appears to be a significant drag on the income statement. Without a clear inflection in revenue velocity, the current cost structure may continue to pressure the company's financial viability, necessitating a more disciplined approach to overhead management.

Liquidity Risks and Commercial Hurdles

Data from recent filings indicates that with cash and equivalents at approximately $1.1 million against ongoing quarterly operating losses, the company faces a precarious liquidity profile that may force dilutive financing, a risk that short-sellers likely emphasize given the slow adoption of the CompuFlo platform.

The disconnect between the company's technological potential and its immediate financial sustainability warrants significant caution. Investors should investigate whether the current cash runway is sufficient to support the necessary commercialization efforts or if the firm is approaching a critical juncture that will require external capital to survive.

MLSS — Frequently Asked Questions

Quick answers to the most common questions about buying MLSS stock.

What was Milestone Scientific Inc.'s (MLSS) revenue in 2025?

For fiscal year 2025, Milestone Scientific Inc. (MLSS) reported total revenue of $9.0M. This represents a 2891.3% increase compared to $0.3M in 1996.

Is Milestone Scientific Inc. (MLSS) profitable?

Milestone Scientific Inc. (MLSS) reported a net loss of $5.7M for the fiscal year ending 2025.

What is Milestone Scientific Inc.'s operating profit margin?

Milestone Scientific Inc. (MLSS) reported an operating income of $-5.7M, resulting in an operating profit margin of -63.5%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Milestone Scientific Inc.'s gross profit and gross margin?

Milestone Scientific Inc. (MLSS) generated $6.3M in gross profit for the year, representing a gross profit margin of 70.5%. This demonstrates the company's core pricing power and production efficiency.